RankAlpha logo
Back to Rankings

MREO

Mereo BioPharma GroupC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The post-earnings company update kept three forward hooks alive: setrusumab regulatory discussions are underway, alvelestat partnering remains active, and cash guidance into mid-2027 was reaffirmed. With a market cap near reported cash, even modest external validation on setrusumab or alvelestat could move the shares materially.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Alvelestat Phase 3 timing appears dependent on securing a partner, so delay or weak deal terms would prolong the value gap.
Momentum
91
Value
41
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.24 · Bull $0.45 · Bear $0.12
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $2.00
Why
Momentum91 · Δ7d -
Value41 · Δ7d +0.1
Sentiment31 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
91
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
31
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade C. Momentum 91.0 / Value 41.1 / Sentiment 31.2

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$48.81M
Beta
0.31
Shares Out
159.62M
P/E (TTM) · Derived
-1.2
P/S (TTM)
152.96
P/FCF (TTM) · Derived
-1.81
Rev YoY
-
EPS YoY
-49.3%
Gross Margin
-162.9%
Op Margin
-9398.2%
Net Debt
-$40.79M
Current Ratio
6.48
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology